Anti-fibrotic Drugs for Crohn's Disease: Ready for Prime Time?

Marjorie Argollo, Daniela Gilardi, Giulia Roda, Gionata Fiorino, Laurent Peyrin-Biroulet, Silvio Danese

Research output: Contribution to journalReview article

Abstract

Intestinal fibrosis, driven by chronic inflammation in Crohn's disease, can be defined as an excessive accumulation of extracellular matrix in the affected gut segment ultimately leading to an impaired wound healing and cumulative tissue damage, possibly resulting in organ dysfunction, formation of stenotic lesions and necessity of surgical intervention. Despite continuous advances in developing novel treatment modalities targeting different pathways to control chronic gut inflammation in CD, no effective anti-fibrotic agents have been released, to date. Thus, a better understanding of the molecular and cellular mechanisms underlying intestinal fibrosis is key to move this area of investigation forward.

Original languageEnglish
Pages (from-to)47-56
Number of pages10
JournalCurrent Pharmaceutical Design
Volume25
Issue number1
DOIs
Publication statusPublished - 2019

    Fingerprint

Keywords

  • Constriction, Pathologic
  • Crohn Disease/drug therapy
  • Fibrosis/drug therapy
  • Gastrointestinal Agents
  • Humans
  • Inflammation
  • Intestines/pathology

Cite this